|
WO2009091531A2
(en)
*
|
2008-01-16 |
2009-07-23 |
The General Hospital Corporation |
Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
|
|
WO2011140393A1
(en)
|
2010-05-05 |
2011-11-10 |
Prolynx Llc |
Controlled release from macromolecular conjugates
|
|
HUE052285T2
(hu)
|
2011-06-06 |
2021-04-28 |
Starpharma Pty Ltd |
Makromolekulák
|
|
WO2013036857A1
(en)
*
|
2011-09-07 |
2013-03-14 |
Prolynx Llc |
Sulfone linkers
|
|
SG11201400444VA
(en)
|
2011-09-07 |
2014-04-28 |
Prolynx Llc |
Hydrogels with biodegradable crosslinking
|
|
US9545449B2
(en)
*
|
2012-05-11 |
2017-01-17 |
Advanced Proteone Therapeutics Inc. |
Site-specific labeling and targeted delivery of proteins for the treatment of cancer
|
|
WO2014116717A1
(en)
*
|
2013-01-22 |
2014-07-31 |
Prolynx Llc |
Sealants having controlled degradation
|
|
EP3010486B1
(en)
|
2013-06-19 |
2023-11-22 |
The Regents of The University of California |
Chemical structures for localized delivery of therapeutic agents
|
|
JP2016534064A
(ja)
*
|
2013-10-22 |
2016-11-04 |
プロリンクス エルエルシー |
ソマトスタチン及びその類似体のコンジュゲート
|
|
CN105813653B
(zh)
*
|
2013-12-19 |
2020-06-26 |
西雅图基因公司 |
与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
|
|
AU2015229014B2
(en)
*
|
2014-03-14 |
2019-07-25 |
The Regents Of The University Of California |
TCO conjugates and methods for delivery of therapeutic agents
|
|
KR102518217B1
(ko)
|
2016-01-08 |
2023-04-04 |
아센디스 파마 그로우쓰 디스오더스 에이/에스 |
낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제
|
|
JP6968802B2
(ja)
|
2016-01-08 |
2021-11-17 |
アセンディス ファーマ グロース ディスオーダーズ エー／エス |
環部分にキャリア結合を有するｃｎｐプロドラッグ
|
|
US10835578B2
(en)
|
2016-01-08 |
2020-11-17 |
Ascendis Pharma Growth Disorders A/S |
CNP prodrugs with large carrier moieties
|
|
CA3008015A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
|
|
AU2017205693B2
(en)
|
2016-01-08 |
2022-03-31 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with low initial NPR-B activity
|
|
EP4710947A3
(en)
|
2016-01-08 |
2026-06-17 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with reduced side-effects
|
|
SI3423103T1
(sl)
|
2016-03-01 |
2024-12-31 |
Ascendis Pharma Bone Diseases A/S |
Predzdravila PTH
|
|
CA3016814A1
(en)
|
2016-03-16 |
2017-09-21 |
Prolynx Llc |
Extended release conjugates of exenatide analogs
|
|
AU2017295938C1
(en)
|
2016-07-13 |
2021-10-07 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
|
RU2768747C2
(ru)
|
2016-09-29 |
2022-03-24 |
Асцендис Фарма Гроус Дизордерс А/С |
Комбинаторная терапия с агонистами cnp контролируемого высвобождения
|
|
KR102611820B1
(ko)
|
2016-09-29 |
2023-12-07 |
아센디스 파마 본 디지즈 에이/에스 |
낮은 피크 대 트로프 비를 가진 pth 화합물
|
|
HUE063235T2
(hu)
|
2016-09-29 |
2024-01-28 |
Ascendis Pharma Bone Diseases As |
Adagolási rendszer szabályozott leadású PTH vegyülethez
|
|
JP7039574B2
(ja)
|
2016-09-29 |
2022-03-22 |
アセンディス ファーマ ボーン ディジージズ エー／エス |
放出制御ｐｔｈ化合物の漸増用量設定
|
|
TWI773730B
(zh)
|
2017-02-22 |
2022-08-11 |
瑞典商阿斯特捷利康公司 |
治療性樹枝狀聚合物
|
|
JP7216006B2
(ja)
|
2017-03-22 |
2023-01-31 |
ジェネンテック， インコーポレイテッド |
ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
|
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
|
US20200323962A1
(en)
*
|
2017-09-19 |
2020-10-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Lipophilic peptide prodrugs
|
|
EP3684785B1
(en)
|
2017-09-19 |
2024-10-02 |
Technische Universität München |
N-methylated cyclic peptides and their prodrugs
|
|
JP2021510702A
(ja)
|
2018-01-12 |
2021-04-30 |
プロリンクス エルエルシー |
相乗的がん治療
|
|
WO2019177740A1
(en)
*
|
2018-03-12 |
2019-09-19 |
Boston Scientific Scimed, Inc. |
Scavenging methods, and scavenging system for radiocontrast agents
|
|
CA3093083A1
(en)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma A/S |
Conjugates
|
|
US12565525B2
(en)
|
2018-03-28 |
2026-03-03 |
Ascendis Pharma Oncology Division A/S |
IL-2 conjugates
|
|
CA3099620A1
(en)
|
2018-05-18 |
2019-11-21 |
Ascendis Pharma Bone Diseases A/S |
Starting dose of pth conjugates
|
|
US12071517B2
(en)
|
2018-07-19 |
2024-08-27 |
Starpharma Pty Ltd. |
Therapeutic dendrimer
|
|
EP3823961A4
(en)
|
2018-07-19 |
2022-06-08 |
Starpharma Pty Limited |
THERAPEUTIC DENDRIMER
|
|
CA3114272A1
(en)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Degradable hyaluronic acid hydrogels
|
|
CA3114056A1
(en)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Treatment of infections
|
|
EP3856256A1
(en)
|
2018-09-26 |
2021-08-04 |
Ascendis Pharma A/S |
Novel hydrogel conjugates
|
|
TW202027794A
(zh)
|
2018-10-03 |
2020-08-01 |
瑞士商諾華公司 |
血管生成素樣３多肽之持續遞送
|
|
SG11202104966XA
(en)
|
2019-01-04 |
2021-06-29 |
Ascendis Pharma Oncology Div A/S |
Sustained local drug levels for innate immune agonists
|
|
SG11202105835YA
(en)
|
2019-01-04 |
2021-07-29 |
Ascendis Pharma Oncology Div A/S |
Conjugates of pattern recognition receptor agonists
|
|
EP3906018A1
(en)
|
2019-01-04 |
2021-11-10 |
Ascendis Pharma Oncology Division A/S |
Induction of sustained local inflammation
|
|
AU2020205029A1
(en)
|
2019-01-04 |
2021-06-24 |
Ascendis Pharma Oncology Division A/S |
Minimization of systemic inflammation
|
|
EP3923906A1
(en)
|
2019-02-11 |
2021-12-22 |
Ascendis Pharma Growth Disorders A/S |
Dry pharmaceutical formulations of cnp conjugates
|
|
AU2020221491B2
(en)
|
2019-02-11 |
2025-02-27 |
Ascendis Pharma Bone Diseases A/S |
Liquid pharmaceutical formulations of PTH conjugates
|
|
MX2021011997A
(es)
*
|
2019-04-05 |
2021-11-04 |
Prolynx Llc |
Enlazadores de conjugacion mejorados.
|
|
WO2020219943A1
(en)
*
|
2019-04-26 |
2020-10-29 |
Prolynx Llc |
Slow-release cytokine conjugates
|
|
WO2020247151A1
(en)
|
2019-06-05 |
2020-12-10 |
Boston Scientific Scimed, Inc. |
Click chemistry capturable platinum-based antineoplastic agents
|
|
WO2020254607A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pd properties
|
|
WO2020254612A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
|
|
EP3986477A1
(en)
*
|
2019-06-21 |
2022-04-27 |
Ascendis Pharma A/S |
CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
|
|
WO2020254617A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pk properties
|
|
TW202114738A
(zh)
|
2019-06-21 |
2021-04-16 |
丹麥商阿仙帝斯製藥公司 |
抗ctla4結合物
|
|
CA3143278A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Tyrosine kinase inhibitor conjugates
|
|
WO2020254613A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
|
|
WO2021067458A1
(en)
*
|
2019-09-30 |
2021-04-08 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Protein-macromolecule conjugates and methods of use thereof
|
|
JP2023510790A
(ja)
|
2020-01-13 |
2023-03-15 |
アセンディス ファーマ ボーン ディジージズ エー／エス |
副甲状腺機能低下症の治療
|
|
WO2021224169A1
(en)
|
2020-05-04 |
2021-11-11 |
Ascendis Pharma A/S |
Hydrogel irradiation
|
|
CA3178074A1
(en)
|
2020-06-03 |
2021-12-09 |
Nina Gunnarsson |
Il-2 sequences and uses thereof
|
|
AU2021335032A1
(en)
|
2020-08-28 |
2023-03-09 |
Ascendis Pharma Oncology Division A/S |
Glycosylated IL-2 proteins and uses thereof
|
|
IL301411A
(en)
|
2020-09-28 |
2023-05-01 |
Ascendis Pharma Bone Diseases As |
Improvement of physical and mental well-being of patients with hypoparathyroidism
|
|
EP4314035A1
(en)
|
2021-04-01 |
2024-02-07 |
Ascendis Pharma A/S |
Use of long-acting growth hormone for treating inflammation-induced diseases
|
|
AU2022350937A1
(en)
|
2021-09-22 |
2024-03-21 |
Ascendis Pharma Bone Diseases A/S |
Long-acting pth compound treatments
|
|
WO2023069510A1
(en)
*
|
2021-10-19 |
2023-04-27 |
The United States Government As Represented By The Department Of Veterans Affairs |
Cannabinoid compositions for gastroesophageal disorders
|
|
JP2024546134A
(ja)
|
2021-12-13 |
2024-12-17 |
アセンディス ファーマ オンコロジー ディヴィジョン エー／エス |
Ｔｌｒ７／８アゴニストを用いたがん治療
|
|
AU2022413318A1
(en)
|
2021-12-13 |
2024-05-16 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
AU2023276829A1
(en)
|
2022-05-23 |
2024-10-31 |
Ascendis Pharma Growth Disorders A/S |
Liquid pharmaceutical formulations of cnp compounds
|
|
CN114874624B
(zh)
*
|
2022-05-27 |
2023-04-07 |
深圳市博致远科技有限公司 |
一种导热吸波室温固化硅橡胶产品及其制备方法
|
|
JP2025537527A
(ja)
|
2022-11-02 |
2025-11-18 |
アセンディス ファーマ ボーン ディジージズ エー／エス |
２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
|
|
TW202434299A
(zh)
|
2023-01-05 |
2024-09-01 |
丹麥商阿仙帝斯製藥公司 |
製造水凝膠微球之方法
|
|
TW202430223A
(zh)
|
2023-01-05 |
2024-08-01 |
丹麥商阿仙帝斯眼科製藥有限公司 |
用於治療眼部病症之藥物結合物
|
|
EP4676535A1
(en)
|
2023-03-06 |
2026-01-14 |
Ascendis Pharma A/S |
Multi-albumin binding compounds
|
|
WO2024184352A1
(en)
|
2023-03-06 |
2024-09-12 |
Ascendis Pharma A/S |
Drug compounds comprising albumin-binding moieties
|
|
IL323019A
(en)
|
2023-03-06 |
2025-10-01 |
Ascendis Pharma As |
Drug compounds with an albumin-binding moiety
|
|
KR20250162619A
(ko)
|
2023-03-20 |
2025-11-18 |
아센디스 파마 그로우쓰 디스오더스 에이/에스 |
연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
|
|
EP4709423A1
(en)
|
2023-05-09 |
2026-03-18 |
Ascendis Pharma Oncology Division A/S |
Novel cancer treatments with il-2 conjugates
|
|
EP4773987A1
(en)
|
2023-09-04 |
2026-07-15 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment of chronic kidney disease
|
|
TW202547452A
(zh)
*
|
2024-03-29 |
2025-12-16 |
美商瑪哈醫療公司 |
可裂解酯類化合物及其用途
|
|
WO2026013138A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Compounds with improved albumin-binding
|
|
WO2026013136A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding compounds
|
|
WO2026013135A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding reagents
|
|
WO2026120177A1
(en)
|
2024-12-06 |
2026-06-11 |
Ascendis Pharma A/S |
Novel long-acting degrader conjugates
|
|
WO2026139471A1
(en)
|
2024-12-23 |
2026-07-02 |
Ascendis Pharma Growth Disorders A/S |
Use of cnp or cnp conjugates such as navepegritide to treat leg curvature in patients with skeletal dysplasia
|
|
WO2026150105A1
(en)
|
2025-01-13 |
2026-07-16 |
Ascendis Pharma A/S |
Fgf23 degrader conjugates
|